Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With...
The benefit of any treatment for any disease should be judged by whether it improves either survival or its quality. For adjuvant treatment of cancer, effects on overall survival (OS) are paramount:...
View ArticleClik here to view.
Validation Institute Independently Certifies VIVIO Delivered 39% Lower PMPM...
San Leandro, CA – VIVIO, the leading drug outcomes company, proudly announces third-party validation of specialty drug savings delivered for VIVIO customers. Validation Institute independently...
View ArticlePatients Often Lose in the Battle between Pharma and PBMs
“It’s the law unintended consequences,” Pramod John, Ph.D., chief executive officer of Vivio Health. “The ACA’s intent was not that providers now can charge whatever they wanted for service, whether a...
View ArticleWhy biosimilars will fail: and what we can do about it
Humira biosimilars have given employers and policy makers a false sense of security about impending cost relief, but all that’s happened is the health industry has once again succeeded in making us...
View ArticleHow Mark Cuban’s Cost Plus Drugs has been turned into an insurance benefit
Mark Cuban Cost Plus Drug Co. is most known for selling cheap prescription drugs directly to consumers through the mail, but those cheap prices have been turned into a benefits solution for health...
View ArticleThe Accelerated Approval Program for Cancer Drugs — Finding the Right Balance
The Food and Drug Administration (FDA) approves about two thirds of new cancer drugs on the basis of clinical trials that use surrogate end points, such as laboratory values or radiographic findings,...
View ArticlePerspectives on Cancer Therapy Development
I vividly recall a young veteran with a highly treatable and potentially curable cancer. We quickly reached what seemed a “fork in the road.” Two effective therapies were available: one inexpensive and...
View ArticleWhy Better Outcomes Cost Less
VIVIO CEO, Pramod John, speaks with UK-based Consilium Scientific. The paradox: Why can’t we reject high costs and subpar drug quality? Delve into healthcare inefficiencies driving this disparity and...
View ArticleExposing the Hidden Costs Behind Prescriptions
Pramod John, CEO of VIVIO Health, discusses issues with drug pricing and competition in the pharmaceutical industry. He talks about how the current system incentivizes higher spending on healthcare...
View ArticleCongressional Investigation of RevAssist-Linked and General Pricing...
In 2022, the US Congress passed the Inflation Reduction Act (IRA) to address high drug costs and limited drug accessibility. IRA’s passage followed a 2019-2021 investigation by the House of...
View ArticleA ‘HIT-chat’ between Pramod John and Tobias Kennedy
Mark Cuban said, “If you’re using one of the big 3 pharmacy benefit managers, you’re getting ripped off. Period.” And then I said, “Oh, man—we NEED to do an episode on this.” …and then I went and got...
View Article